+1 (602) 839-6900

901 E. Willetta St., Phoenix, AZ 85006

FDA Panel Declines to Endorse Alzheimer’s Drug — The New York Times

Nov 9, 2020 | News

FDA Panel Declines to Endorse Alzheimer’s Drug — The New York Times

The drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. But the advisory panel said there was not enough evidence of its effectiveness in slowing cognitive decline.

Click here to read the full article from The New York Times

Recent Posts

New ASU Health Headquarters helps advance Alzheimer’s research

Mar 12, 2025

Headquarters for innovations to help every family have a healthier future will be in downtown Phoenix Bioscience Core and open in time for fall 2028 semester. Click Here to Read the Full Story  The post New ASU Health Headquarters helps advance Alzheimer’s research...

New Alzheimer’s prevention trial receives $74.5 million NIH grant

Nov 19, 2024

Two-part trial to build on landmark Colombian prevention study of people at near-certain genetic risk for early-onset Alzheimer’s disease PHOENIX (Thursday, Nov. 14) – A new Alzheimer’s prevention study has received a $74.5 million five-year grant from the National...